MAY 17 - 19, 2018
17 A 19 DE MAIO, 2018



Abstract Submission


1. Only papers related to Breast Cancer that have not been published shall be accepted.

2. Each paper shall point out the preferred type of presentation whether oral or poster.

3. Typing of the abstract:
- Use line spacing of 1 with Font 10 (Times New Roman). Leave 1.5 cm margins both sides and justify the text.
- Maximum number of characters: 2500 (Title, authors, Institution and Key words are not included).
- Do not use paragraphs. In the event of using abbreviations and acronyms, explain them at the first time they are used in the text.
- Do not start sentences with numbers.
- Do not use tables or charts. They might be exhibited on the day of the oral presentation or in the poster text.
- Text division must obey the following order: title; authors; institution; objectives; methodology; results; conclusion; key words.
For case reports, there is no need to follow such structure.
4. Authors: - 8 authors (maximum) are allowed (one author and seven co-authors) per paper. - The author who submits the paper must be registered in the Event and his/her registration must be paid off. - The presenting author must be registered in the Event as well and his/her registration must be paid off. - Authors shall be mentioned by their first and last names, separating authors using comma. Eg.: Antônio B. Silva, Fábio G. Santos. - Institution where the work has been carried out. -Abstracts shall be written in English

5. Papers shall be submitted through the site

6. The deadline for submit your abstract has been extended until April 2.

7. The Judging Committee will only select papers that are relevant to the scientific community.

8. The Scientific Committee shall evaluate all the papers approving or not their presentation. Due to space limitations for the presentations, the Committee also has the right to relocate certain papers from one session to another, depending on time and space availability.

9. Authors of selected papers shall be notified in advance by email.

10. The best papers shall be selected for oral presentation pursuant to the judgment of the Scientific Committee. The others shall be presented in an e-poster format during a particular session.

11. Each oral presentation will last ten (10) minutes for the paper presentation using Data Show, followed by a five-minute panel discussion, with questions from the audience.

12. The posters shall be sent in an e-poster format using power point.

13. Papers that do not comply with the abovementioned instructions shall be automatically disregarded.

14. In the event of a paper not being accepted there will be no reimbursement of the registration fee excepting those that requested it on the day mentioned in the online registration tab.

15. The best paper will receive the award "Professor José Aristodemo Pinotti" in which the following will be granted: transportation, accommodation and registration at the San Antonio Breast Cancer Symposium 2018. The award “Professor Carlos Inácio de Paula” will grant the amount of 1,500.00 (one thousand five hundred reais)

16. The event will also grant the YOUNG RESEARCHER AWARD: "Professor Claudio Kemp." This award is intended to encourage young researchers. We shall only take into account papers whose main author (first author) is under the age of 35. Therefore, it is essential to inform the age of the first author during the registration of the paper. Papers presented orally or in a poster format shall compete equally. The best paper under this category will be awarded with air tickets, hotel and registration for the event Jornada Paulista de Mastologia – JPM 2018.

17. The assessment will be made by peers, with a minimum of two evaluators per paper who are not aware of the authorship of such paper and the evaluation of the second examiner. The evaluation criteria are the following: (1) relevance and originality; (2) clarity and relevance of the objectives and consistency with the methodology; (3) the appropriateness of the research design; (4) description of the methods, statistical analysis; (5) outcome importance, clinical applicability and impact."